Skip to Main Content

Advertisement

Skip Nav Destination

Daniel DeAngelo, MD, PhD: BLU-285 Active, Well-Tolerated in Advanced Systemic Mastocytosis

December 30, 2021
Dr. DeAngelo discusses results from the phase I study presented as a plenary abstract at this year’s meeting, evaluating the KIT inhibitor BLU-285 in patients with advanced systemic mastocytosis – including those whose disease progressed on midostaurin.

Advertisement

Connect with us:

CURRENT ISSUE
September 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement